Chardan analyst Gbola Amusa is placing his confidence behind AveXis Inc (NASDAQ:AVXS) even in light of competitors Biogen Inc (NASDAQ:BIIB) and Ionis Pharmaceuticals …
In a research report released Thursday, Chardan Capital analyst Gbola Amusa reiterated a Neutral rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR), with a …
Chardan Capital analyst Gbola Amusa weighed in today with a favorable report on La Jolla Pharmaceutical Company (NASDAQ:LJPC), reiterating a Buy rating and raising the price target …
In a research report released today, Chardan Capital analyst Gbola Amusa downgraded shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) from a Buy to a Hold raring, while …
In a research report issued today, Chardan analyst Gbola Amusa maintained a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR), with a $36 price …
In a research note issued today, Chardan analyst Gbola Amusa maintained a Buy rating on shares of Uniqure NV (NASDAQ:QURE), and reduced the price target to …
In a research report issued today, Chardan analyst Gbola Amusa reiterated a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR), and reduced the price …
Chardan analyst Gbola Amusa came out today with some commentary on Esperion Therapeutics Inc (NASDAQ:ESPR)’s top-line results from ETC-1002-014, a Phase 2 exploratory study evaluating the safety …
In a research report issued today, Chardan analyst Gbola Amusa reiterated a Sell rating on Axovant Sciences Ltd. (NYSE:AXON) with a $9.
In a research report issued today, Chardan analyst Gbola Amusa reiterated a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR), while reducing the price target from …
